According to Consort Medical’s financial report for the fiscal year ending April 2014, its Bespak subsidiary is adding a 4,200 sq m facility for the manufacture of a nicotine DPI and a 5,200 sq m facility for the manufacture of a DPI currently known as DEV610 to the existing 19,300 sq m facilities at its King’s Lynn, UK site. The nicotine device will be fully assembled at King’s Lynn, including the drug.
The nicotine DPI facility is nearly complete, the company said, while construction on the DEV610 facility got underway in May 2014 and is expected to continue for approximately one year.
The report adds that its contract with Chiesi for the manufacture of the NEXThaler device has been extended as of April 2014, necessitating an expansion and retrofit of the existing King’s Lynn facility. In addition, the Bespak facility at Milton Keynes has been refurbished for component molding for the nicotine inhaler.
New laboratories and a pilot plant have also been constructed for the Bespak Innovations Centre, and personnel are moving into the new facility.
Bespak announced its contract with British American Tobacco subsidiary Nicoventures for the manufacture of the nicotine DPI in December 2012. The DEV610 project was announced in November 2013.
According to the report, the company also received a development contract with an undisclosed customer in July 2013 for a nasal delivery device. Bespak entered the nasal delivery market in 2011.
According to the company, Bespak manufactures 2.6 billion device components per year and assembles over 500 million devices. To date, it says, it has manufactured more than 600 million Diskus DPIs and over a billion HFA MDI valves.
Read the Consort Medical report.
